Catalent (CTLT) Akcie Kurz
Catalent Kurz
Za posledních 15 let vzrostly tržby Catalent o 7,9 % ročně a dosáhly 4,38 Mld. USD. Zisk na akcii rostl o 46,7 % ročně za posledních 8 let. U Catalent je čistá marže -23,8 % dolů oproti 5,6 % před několika lety. Konsenzuální 12měsíční cílová cena pro Catalent je 64,77 USD, asi nad cenu o 2,0 %. Z 14 analytiků jich 0 doporučuje nákup — celkový konsenzus je Držet.
Cena akcie Catalent
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Catalent a analýza akcií
Nejčastější otázky týkající se akcie Catalent
Catalent Inc is a leading provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With its strategic approach, Catalent offers a broad range of integrated services to ensure efficient drug development and delivery. The company's business model focuses on collaborating with pharmaceutical and biotechnology companies to accelerate their product development process and bring innovative therapies to market. By leveraging its expertise in formulation and development, advanced delivery systems, and manufacturing solutions, Catalent helps its clients optimize their chances of success while delivering high-quality products to patients worldwide.
Catalent Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Catalent Inc in the market include Thermo Fisher Scientific Inc, Lonza Group Ltd, and Patheon N.V.
Catalent Inc is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products. With a rich history spanning over 80 years, Catalent has established itself as a trusted partner to pharmaceutical and biotech companies worldwide. The company was founded in 2007 through the merger of RP Scherer Corporation and Cardinal Health's pharmaceutical technologies and services segment. Catalent Inc has continuously evolved and expanded its capabilities, offering a wide range of solutions including drug development, manufacturing, packaging, and supply chain services. Today, Catalent Inc is recognized for its innovative approach, cutting-edge technologies, and commitment to delivering exceptional customer value in the healthcare industry.
Catalent Inc, a leading global provider of advanced delivery technologies and development solutions, has achieved numerous significant milestones over the years. One notable achievement is its successful acquisition of Cook Pharmica LLC, which expanded its biologics development and manufacturing capabilities. Additionally, the company has strengthened its global presence by opening new facilities in strategic locations, such as a state-of-the-art biomanufacturing facility in Bloomington, Indiana. Catalent Inc has also received various awards and recognition for its innovation, including being named the Contract Development and Manufacturing Organization of the Year by Pharma Integrates. These milestones highlight Catalent Inc's commitment to growth, innovation, and delivering advanced solutions to its customers.
Catalent Inc is primarily present in multiple countries and regions. With a global presence, this innovative company operates in North America, Europe, Asia Pacific, and Latin America. Catalent Inc has established manufacturing, development, and distribution facilities in various locations across the United States, including New Jersey, Indiana, and Maryland. In Europe, the company operates in multiple countries, including the United Kingdom, Germany, and Italy. In the Asia Pacific region, Catalent Inc has a strong presence in China, Singapore, and Japan. Additionally, the company has operations in Brazil, Argentina, and Mexico, among other countries in Latin America.
Catalent Inc represents key values of innovation, collaboration, and customer focus. With a corporate philosophy centered on driving exceptional experiences and outcomes for patients and customers, Catalent is committed to delivering advanced solutions for the development and manufacturing of pharmaceutical products. The company's dedication to scientific excellence and quality ensures the precise delivery and reliable supply of medicines to improve health globally. Catalent's strong expertise in drug delivery technologies, development solutions, and manufacturing capabilities positions them as a trusted partner in the pharmaceutical industry. Emphasizing continuous improvement and sustainable practices, Catalent Inc remains dedicated to making a meaningful impact in healthcare.
Analytici aktuálně stanovují průměrnou cílovou cenu 64,77 USD pro akcii Catalent (medián: 64,77 USD), tedy +2,0 % vůči poslední ceně. Konsensus vychází z 14 hodnocení analytiků.
14 analytiků aktuálně hodnotí akcii Catalent: 0 doporučuje koupit, 11 držet a 3 prodat. Pro rok 2026 analytici očekávají u Catalent tržby 5,00 Mld. USD a zisk na akcii 1,75 USD.
Při aktuálním kurzu se akcie Catalent obchoduje za 57,55 EUR (63,48 USD).
Akcie Catalent (CTLT) je kótována na 4 burzách, mimo jiné: NYSE (CTLT), SIX (Zürich) (0C8.SW), Frankfurt (0C8.F), München (0C8.MU).
Catalent Inc. is a globally operating company that focuses on the development and manufacturing of pharmaceuticals, as well as supporting biotech and pharmaceutical companies. It operates in three business segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. These segments offer a variety of products and services tailored to the different needs of biotech and pharmaceutical companies. Catalent Inc. earns revenue through the sale of its products and services, as well as partnerships and collaborations with other companies. It works closely with its customers to develop customized solutions and achieve a high level of customer satisfaction.
Tržby očekávané za Catalent činí 5,00 Mld. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Catalent činí 318,65 Mil. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Catalent je aktuálně 36,26. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Catalent.
Poměr ceny k tržbám (P/S) Catalent je aktuálně 2,31. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Catalent.
Score kvality pro Catalent je 2/10.
ISIN Catalent je US1488061029. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Catalent je A112H2. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Catalent je CTLT. Symbol tickeru se používá k obchodování akcií Catalent na burze.
Catalent akcie
Catalent Peer Group
Catalent Ticker
Catalent FIGI
Všechny fundamentální údaje o Catalent v podrobné analýze
Naše analýzy akcií společnosti Catalent zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Catalent. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy: